Eurofins Optimed
Gières, 38610, France
NCT Number: NCT03694041
This study aims to evaluate the safety, tolerabilty, pharmacokinetics and pharmacodynamics of single ascending doses and multiple ascending doses of APX-115 in healthy males. This study also aims to evaluate the effect of food consumption on the pharmacokinetics of APX-115 and potential interaction between caffeine and APX-115 in healthy males.
Looking for future studies?
Notify MeHealthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion:
Exclusion:
Drug: APX-115 SAD APX-115 SAD for 1day
Drug: Placebo Placebo for 1day
Drug: APX-115 MAD APX-115 MAD repeatedly administered.
Matching study drug will be repeatedly administered.
A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.
A metabolic probe will be administered with and without APX-115.
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 8
Time frame: Up to Day 17
Time frame: Up to Day 17
Time frame: Up to Day 17
Time frame: Up to Day 17
Time frame: Up to Day 4 post-dose
Time frame: Up to Day 4 post-dose
Time frame: Up to Day 4 post-dose
Time frame: Up to Day 4 post-dose
Time frame: Up to Day 4 post-dose
Time frame: Up to Day 4 post-dose
Time frame: Up to Day 4 post-dose
Time frame: Up to Day 4 post-dose
Time frame: Up to Day 4 post-dose
Time frame: Up to Day 4 post-dose
Time frame: Up to Day 4 post-dose
Time frame: Up to Day 4 post-dose
Time frame: Up to Day 4 post-dose
Time frame: Up to Day 5
Time frame: Up to Day 5
Time frame: Up to Day 5
Time frame: Up to Day 5
Time frame: Up to Day 5
Time frame: Up to Day 5
Time frame: Up to Day 11
Time frame: Up to Day 11
Time frame: Up to Day 11
Time frame: Up to Day 11
Time frame: Up to Day 11
Time frame: Up to Day 11
Time frame: Up to Day 11
Time frame: Up to Day 4 post-dose
Time frame: Up to Day 4 post-dose
Time frame: Up to Day 4 post-dose
Time frame: Up to Day 4 post-dose
Time frame: Up to Day 4 post-dose
Aptabio Therapeutics, Inc.
Industry
Double Blind, Randomized Study Assessing the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses or Multiple Ascending Doses of APX-115 in Healthy Male Volunteers.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00696865
Healthy, Safety
Kanagawa, Japan
View Trial DetailsNCT06717867
Healthy, Safety
Brisbane, Queensland, Australia
View Trial DetailsNCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial Details